Stem cells as in vitro models of disease

Current Stem Cell Research and Therapy

Volumn 2, Issue 4, 2007, Pages 280-292

  Ruiz Lozano, Pilar ^a   Rajan, Prithi ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Autism; Cardiac; Embryonic; Glioma; Neural; Stem cells

Indexed keywords

ANTICONVULSIVE AGENT; BASIC FIBROBLAST GROWTH FACTOR; BETA CATENIN; EPIDERMAL GROWTH FACTOR; GALANTAMINE; GLYCOPROTEIN GP 130; HOMEODOMAIN PROTEIN; JANUS KINASE; MELATONIN; MICRORNA; MIRTAZAPINE; MITOGEN ACTIVATED PROTEIN KINASE; OCTAMER TRANSCRIPTION FACTOR 4; OXYGEN; OXYTOCIN; REELIN; RETINOID; SECRETIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; STAT3 PROTEIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP2; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; WNT PROTEIN; WNT1 PROTEIN; WNT2 PROTEIN;

AUTISM; BEHAVIOR THERAPY; BIOCHEMISTRY; BRAIN TUMOR; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHROMOSOME 15Q; CHROMOSOME 1P; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME 7Q; CHROMOSOME REARRANGEMENT; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MODEL; EMBRYONIC STEM CELL; GENE EXPRESSION; GLIOMA; HEART DEVELOPMENT; HEMATOPOIETIC STEM CELL; HUMAN; HYPERBARIC OXYGEN; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL; VERTEBRATE;

ANIMALS; AUTISTIC DISORDER; BRAIN NEOPLASMS; CARDIOVASCULAR DISEASES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HEART; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; NEURODEGENERATIVE DISEASES; RATS; STAT TRANSCRIPTION FACTORS; STEM CELLS; WNT PROTEINS;

EID: 38349182201     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488807782793772     Document Type: Review

References (161)

1. Baker DE, Harrison NJ, Maltby E, et al. Adaptation to culturo of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol 2007; 25(2): 207-15.
2. Rajan P, Snyder E. Neural stem cells and their manipulation. Methods Enzymol 2006; 419: 23-52.
3. Rajan P, Panchision DM, Newell LF, McKay RD. BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. J Cell Biol 2003; 161(5): 911-21.
4. Johe KK, Hazel TG, Muller T, Dugich-Djordjevic MM, McKay RD. Single factors direct the differentiation of stem cells from the fetal and -adult central nervous system. Genes Dev 1996; 10(24): 3129-40.
5. Israsena N, Hu M, Fu W, Kan L, Kessler JA. The presence of FGF2 signaling determines whether beta-catenin exerts effects on proliferation or neuronal differentiation of neural stem cells. Dev Biol 2004; 268(1): 220-31.
6. Viti J, Gulacsi A, Lillien L. Wnt regulation of progenitor maturation in the cortex depends on Shh or fibroblast growth factor 2. J Neurosci 2003; 23(13): 5919-27.
7. Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 2002; 297(5580): 365-69.
8. Megason SG, McMahon AP. A mitogen gradient of dorsal midline Wnts organizes growth -in the CNS. Development 2002; 129(9): 2087-98.
9. Sommer L. Multiple roles of canonical Wnt signaling in cell cycle progression and cell lineage specification in neural development. Cell Cycle 2004; 3(6): 701-03.
10. Tropepe V, Craig CG, Morshead CM, van der Kooy D. Transforming growth factor-alpha null and senescent mice show decreased neural progenitor cell prolifeiration in the forebrain subependyma. J Neurosci 1997; 17(20): 7850-59.
11. Parmacek MS, Epstein JA. Pursuing cardiac progenitors: regeneration redux. Cell 2005; 120(3): 295-98.
12. Lyngbaek S, Schneider M, Hansen JL, Sheikh SP. Cardiac regeneration by resident stem and progenitor cells in the adult heart. Basic Res Cardiol 2007; 102(2): 101-114.
13. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 2003; 425(6961): 968-73.
14. Andrade J, Lam JT, Zamora M, et al. Predominant fusion of bone marrow-derived cardiomyocytes. Cardiovasc Res 2005; 68(3): 387-93.
15. Franco D, Moreno N, Ruiz-Lozano P. Cardiovascular development: towards biomedical applicability: Non-resident stem cell populations in regenerative cardiac medicine. Cell Mol Life Sci 2007; 64(6): 683-91.
16. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry 2005; 162(6): 1133-41.
17. Diagnostic and statistical manual of mental disorders (DSMIV). American Psychiatric Association, Washington, DC 1994; 4th Ed.
18. Trottier G, Srivastava L, Walker CD. Etiology of infantile autism: a review of recent advances in genetic and neurobiological research. J Psychiatry Neurosci 1999; 24(2): 103-15.
19. Tordjman S, Gutknecht L, Carlier M, et al. Role of the serotonin transporter gene in the behavioral expression of autism. Mol Psychiatry 2001; 6(4):434-39.
20. Piven J, Bailey J, Ranson BJ, Arndt S. No difference in hippocampus volume detected on magnetic resonance imaging in autistic individuals. J Autism Dev Disord 1998; 28(2): 105-10.
21. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001; 57(9): 1618-28.
22. Purcell AE, Jeon OH, Pevsner J. The abnormal regulation of gene expression in autistic brain tissue. J Autism Dev Disord 2001; 31(6): 545-49.
23. Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science 2003; 302(5646): 826-30.
24. Bailey A, Le Conteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995; 25(1): 63-77.
25. Szatmari P, Paterson AD, Zwaigenbaum L, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 2007; 39(3): 319-28.
26. Schanen NC. Epigenetics of autism spectrum disorders. Human Molecular Genetics 2006; 15(2): R138-R150.
27. Dong E, Guidotti A, Grayson DR, Costa E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci USA 2007; 104(11): 4676-81.
28. Mitchell CP, Chen Y, Kundakovic M, Costa E, Grayson DR. Histone deacetylase inhibitors decrease reelin promoter methylation in vitro. J Neurochem 2005; 93(2): 483-92.
29. Grayson DR, Chen Y, Costa E, et al. The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/ -) in schizophrenia. Pharmacol Ther 2006; 111(1): 272-86.
30. Herzing LB, Cook EH Jr., Ledbetter DH. Allele-specific expression analysis by RNA-FISH demonstrates preferential maternal expression of UBE3A and imprint maintenance within 15q11-q13 duplications. Hum Mol Genet 2002; 11(15): 1707-18.
31. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 2005; 37(1): 31-40.
32. Samaco RC, Hogart A, LaSalle JM. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Genet 2005; 14(4):483-92.
33. Courchesne E, Carper R, Akshoomoff N. Evidence of brain over-growth in the first year of life in autism. JAMA 2003; 290(3): 337-44.
34. Aylward EH, Minshew NJ, Field K, Sparks BF, Singh N. Effects of age on brain volume and head circumference in autism. Neurology 2002; 59(2): 175-83.
35. Bailey A, Luthert P, Bolton P, Le Couteur A, Rutter M, Harding B. Autism and megalencephaly. Lancet 1993; 341(8854): 1225-26.
36. Davidovitch M, Patterson B, Gartside P. Head circumference measurements in children with autism. J Child Neurol 1996; 11(5): 389-93.
37. Courchesne E. Brain development in autism: Early overgrowth followed by premature arrest of growth. Ment Ret Dev Dis 2004; 10: 106-111.
38. van Karnebeek CD, van Gelderen I, Nijhof GJ, et al. An etiological study of 25 mentally retarded adults with autism. J Med Genetics 1993; 39: 205-213.
39. Bauman ML. Microscopic neuroanatomic abnormalities in autism. Pediatrics 1991; 87(5 Pt 2): 791-96.
40. Bailey A, Luthert P, Dean A, et al. A clinicopathological study of autism. Brain 1998; 121 (Pt 5): 889-905.
41. Kemper TL, Bauman ML. The contribution of neuropathologic studies to the understanding of autism. Neurol Clin 1993; 11(1): 175-87.
42. Ritvo ER, Freeman BJ, Scheibel AB, et al. Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am J Psychiatry 1986; 143(7): 862-66.
43. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J Autism Dev Disord 2001; 31(6): 537-43.
44. Casanova W, Buxhoeveden DP, Switala AE, Roy E. Minicolumnar pathology in autism. Neurology 2002; 58(3): 428-32.
45. Fatemi SH, Stary JM, Halt AR, Realmuto GR. Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum. J Autism Dev Disord 2001; 31(6): 529-35.
46. Nishikawa S, Goto S, Hamasaki T, Yamada K, Ushio Y. Involvement of reelin and Cajal-Retzius cells in the developmental formation of vertical columnar structures in the cerebral cortex: evidence from the study of mouse presubicular cortex. Cereb Cortex 2002; 12(10): 1024-30.
47. Chenn A, Walsh CA. Increased neuronal production, enlarged forebrains and cytoarchitectural distortions in beta-catenin overexpressing transgenic mice. Cereb Cortex 2003; 13(6): 599-606.
48. Zechner D, Fujita Y, Hulsken J, et al. beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol 2003; 258(2): 406-18.
49. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32(5): 585-89.
50. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007; 61(4): 498-503.
51. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol 2006; 16(5): 621-29.
52. Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006; 16(1-2): 181-86.
53. Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses 2007; 68(6): 1208-27.
54. Wigram T, Gold C. Music therapy in the assessment and treatment of autistic spectrum disorder: clinical application and research evidence. Child Care Health Dev 2006; 32(5): 535-42.
55. LaSalle JM, Hogart A, Thatcher KN. Rett Syndrome: a rosetta stone for understanding the molecular pathologies of autism. International Rev Neurobiol 2005; 71: 131-165.
56. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9(5): 391-405.
57. Nakano I, Kornblum HI. Brain tumor stem cells. Pediatr Res 2006; 59(4 Pt 2): 54R-8R.
58. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23(43): 7274-82.
59. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest 2006; 86(12): 1203-07.
60. Lee JC, Vivanco I, Beroukhim R, et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Med 2006; 3(12): e485.
61. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353(19): 2012-24.
62. Montgomery RB, Moscatello DY, Wong AJ, Cooper JA, Stahl WL. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 1995; 270(51): 30562-66.
63. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65(1): 27-35.
64. Moscatello DY, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 1997; 57(8): 1419-24.
65. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17(2):165-72.
66. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002; 16(21): 2743-48.
67. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002; 297(5586): 1559-61.
68. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444(7120): 761-65.
69. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23(18): 3151-71.
70. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23(23): 5294-304.
71. Panner A, Parsa AT, Pieper RO. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev Anticancer Ther 2006; 6(9): 1313-22.
72. Hentges KE, Sirry B, Gingeras AC, et al. FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc Natl Acad Sci USA 2001; 98(24): 13796-801.
73. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000; 10(1):47-50.
74. Rajan P, McKay RD. Multiple routes to astrocytic differentiation in the CNS. J Neurosci 1998; 18(10): 3620-29.
75. Bonni A, Sun Y, Nadal-Vicens M, et al. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 1997; 278(5337): 477-83.
76. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005; 4(9): 1131-33.
77. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2(6): 315-24.
78. Schaefer LK, Ren Z, Fuller GN, Schaefer TS. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002; 21(13): 2058-65.
79. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005; 65(3): 939-47.
80. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307(5707): 269-73.
81. Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 2005; 280(12): 11528-34.
82. O'Shea JJ, Kanno Y, Chen X, Levy DE. Cell signaling. Stat acetylation-a key facet of cytokine signaling? Science 2005; 307(5707): 217-18.
83. Molne M, Studer L, Tabar V, Ting YT, Eiden MV, McKay RD. Early cortical precursors do not undergo LIF-mediated astrocytic differentiation. J Neurosci Res 2000; 59(3): 301-11.
84. Song MR, Ghosh A. FGF2-induced chromatin remodeling regulates CNTF-mediated gene expression and astrocyte differentiation. Nat Neurosci 2004; 7(3): 229-35.
85. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118(4): 409-18.
86. Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004; 428(6980): 337-41.
87. Zencak D, Lingbeek M, Kostic C, et al. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci 2005; 25(24): 5774-83.
88. Yung WK. Future directions for temozolomide therapy. Semin Oncol 2001; 28(4 Suppl 13):43-46.
89. Ban S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444(7120): 756-60.
90. Khanna KK, Lavin MF, Jackson SP, Mulhem TD. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 2001; 8(11):1052-65.
91. Lavin MF, Scott SP, Kozlov S, Gueven N. Analyzing the regulation and function of ATM. Methods Mol Biol 2004; 281: 163-78.
92. Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem 1999; 274(44): 31127-30.
93. Kastan MB, Lim DS, Kim ST, Yang D. ATM-a key determinant of multiple cellular responses to irradiation. Acta Oncol 2001; 40(6): 686-88.
94. Pellegrini M, Celeste A, Difilippantonio S, et al. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature 2006; 443(7109): 222-25.
95. Bhoumik A, Takahashi S, Breitweiser W, Shiloh Y, Jones N, Ronai Z. ATM-dependent phosphorylation of ATF2 is required for the DNA damage response. Mol Cell 2005; 18(5): 577-87.
96. Allen DM, van-Praag H, Ray J, et al. Ataxia telangiectasia mutated is essential during adult neurogenesis. Genes Dev 2001; 15(5): 554-66.
97. Bodmer R, Jan LY, Jan YN. A new homeobox-containing gene, msh-2, is transiently expressed early during mesoderm formation of Drosophila. Development 1990; 110(3): 661-69.
98. Bodmer R. The gene tinman is required for specification of the heart and visceral muscles in Drosophila. Development 1993; 118(3): 719-29.
99. Tanaka M, Chen Z, Bartunkova S, Yamasaki N, Izumo, S. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development 1999; 126(6): 1269-80.
100. Biben C, Weber R, Kesteven S, et al. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res 2000; 87(10): 888-95.
101. Biben C, Harvey RP. Homeodomain factor Nkx2-5 controls left/right asymmetric expression of bHLH gene eHand during murine heart development. Genes Dev 1997; 11(11): 1357-69.
102. Biben C, Palmer S, Elliott DA, Harvey RP. Homeobox genes and heart development. Cold Spring Harb Symp Quant Biol 1997; 62: 395-403.
103. Stennard FA, Costa MW, Elliott DA, et al. Cardiac T-box factor Tbx20 directly interacts with Nkx2-5, GATA4, and GATA5 in regulation of gene expression in the developing heart. Dev Biol 2003; 262(2): 206-24.
104. McElhinney DB, Geiger E, Blinder J, Benson DW, Goldmuntz E. NKX2.5 mutations in patients with congenital heart disease. J Am Coll Cardiol 2003; 42(9): 1650-55.
105. Elliott DA, Kirk EP, Yeoh T, et al. Cardiac homeobox gene NKX2-5 mutations-and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome. J Am Coll Cardiol 2003; 41(11): 2072-76.
106. Kasahara H, Lee B, Schott JJ, et al. Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease. J Clin Invest 2000; 106(2): 299-308.
107. Pashmforoush M, Lu JT, Chen H, et al. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell 2004; 117(3): 373-86.
108. Prall OW, Menon MK, Solloway MJ, et al. An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. Cell 2007; 128(5): 947-59.
109. Bruneau BG, Nemer G, Schmitt JP, et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 2001; 106(6): 709-21.
110. Bruneau BG, Logan M, Davis N, et al. Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Dev Biol 1999; 211(1): 100-08.
111. Epstein JA. Developing models of DiGeorge syndrome. Trends Genet 2001; 17(10): S13-7.
112. Reeves RH. Down syndrome mouse models are looking up. Trends Mol Med 2006; 12(6):237-40.
113. Davies MP, An RH, Doevendans P, Kubalak S, Chien KR, Kass RS. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 1996; 78(1):15-25.
114. Miller-Hance WC, LaCorbiere M, Fuller SJ, et al. In vitro chamber specification during embryonic stem cell cardiogenesis. Expression of the ventricular myosin light chain-2 gene is independent of heart tube formation. J Biol Chem 1993; 268(33): 25244-52.
115. Terami H, Hidaka K, Shirai M, et al. Efficient capture of cardiogenesis-associated genes expressed in ES cells. Biochem Biophys Res Commun 2007; 355(1): 47-53.
116. Wobus AM, Kaomei G, Shan J, et al. Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J Mol Cell Cardiol 1997; 29(6): 1525-39.
117. Wilson JG, Walkany J. Aortic-arch and cardiac abnormalities in the ofspring of vitamin A deficient rats. Am J Anat 1949; 85(113-115).
118. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313(14): 837-41.
119. Mulder GB, Manley N, Grant J, et al. Effects of excess vitamin A on development of cranial neural crest- derived structures: a neonatal and embryologic study. Teratology 2000; 62(4): 214-26.
120. Dickman ED, Thaller C, Smith SM. Temporally-regulated retinoic acid depletion produces specific neural crest, ocular and nervous system defects. Development 1997; 124(16): 3111-21.
121. Zile MH. Function of vitamin A in vertebrate embryonic development. J Nutr 2001; 131(3): 705-08.
122. Mark M, Ghyselinck NB, Wendling O, et al. A genetic dissection of the retinoid signalling pathway in the mouse. Proc Nutr Soc 1999; 58(3): 609-13.
123. Dyson E, Sucov HM, Kubalak SW, et al. Atrial-like phenotype is associated with embryonic ventricular failure in retinoid X receptor alpha -/- mice. Proc Natl Acad Sci USA 1995; 92(16): 7386-90.
124. Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR, Evans RM. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev 1994; 8(9): 1007-18.
125. Gruber PJ, Kubalak SW, Pexieder T, Sucov HM, Evans RM, Chien KR. RXR alpha deficiency confers genetic susceptibility for aortic sac, conotruncal, atrioventricular cushion, and ventricular muscle defects in mice. J Clin Invest 1996; 98(6): 1332-43.
126. Kubalak SW, Hutson DR, Scott KK, Shannon RA. Elevated transforming growth factor beta2 enhances apoptosis and contributes to abnormal outflow tract and aortic sac development in retinoic X receptor alpha knockout embryos. Development 2002; 129(3): 733-46.
127. Chen J, Kubalak SW, Chien KR. Ventricular muscle-restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development 1998; 125(10):1943-49.
128. Merki E, Zamora M, Raya A, et al. From the Cover: Epicardial retinoid X receptor (alpha) is required for myocardial growth and coronary artery formation. Proc Natl Acad Sci USA 2005; 102(51): 18455-60.
129. Stuckmann I, Evans S, Lassar AB. Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev Biol 2003; 255(2): 334-49.
130. Chen TH, Chang TC, Kang JO, et al. Epicardial induction of fetal cardiomyocyte proliferation via a retinoic acid-inducible trophic factor. Dev Biol 2002; 250(1): 198-207.
131. Uusitalo M, Heikkila M, Vainio S. Molecular genetic studies of Wnt signaling in the mouse. Exp Cell Res 1999; 253(2): 336-48.
132. Schneider VA, Mercola M. Wnt antagonism initiates cardiogenesis in Xenopus laevis. Genes Dev 2001; 15(3): 304-15.
133. Marvin MJ, Di Rocco G, Gardiner A, Bush SM, Lassar AB. Inhibition of Wnt activity induces heart formation from posterior mesoderm. Genes Dev 2001; 15(3): 316-27.
134. Tzahor E, Lassar AB. Wnt signals from the neural tube block ectopic cardiogenesis. Genes Dev 2001; 15(3): 255-60.
135. Lickert H, Kutsch S, Kanzler B, Tamai Y, Taketo MM, Kemler R. Formation of multiple hearts in mice following deletion of beta-catenin in the embryonic endoderm. Dev Cell 2002; 3(2): 171-81.
136. Nakamura T, Sano M, Songyang Z, Schneider MD. A Wnt- and beta -catenin-dependent pathway for mammalian cardiac myogenesis. Proc Natl Acad Sci USA 2003; 100(10):5834-39.
137. Wu X, Golden K, Bodmer R. Heart development in Drosophila requires the segment polarity gene wingless. Dev Biol 1995; 169(2):619-28.
138. Park M, Wu X, Golden K, Axelrod JD, Bodmer R. The wingless signaling pathway is directly involved in Drosophila heart development. Dev Biol 1996; 177(1): 104-16.
139. Naito AT, Shiojima I, Akazawa H, et al. Developmental stage-specific biphasic roles of Wnt/bata-catenin signaling in cardiomyogenesis and hematopoiesis. Proc Natl Acad Sci USA 2006; 103(52): 19812-17.
140. Sachinidis A, Schwengberg S, Hippler-Altenburg R, et al. Identification of small signalling molecules promoting cardiac-specific differentiation of mouse embryonic stem cells. Cell Physiol Biochem 2006; 18(6):303-14.
141. Wu X, Ding S, Ding Q, Gray NS, Schultz PG. Small molecules that induce cardiomyogenesis in embryonic stem cells. J Am Chem Soc 2004; 126(6): 1590-91.
142. Foshay Y, Rodriguez G, Hoel B, Narayan J, Gallicano GI. JAK2/STAT3 directs cardiomyogenesis within murine embryonic stem cells in vitro. Stem Cells 2005; 23(4): 530-43.
143. Zhou X, Quann E, Gallicano GI. Differentiation of nonbeating embryonic stem cells into beating cardiomyocytes is dependent on downregulation of PKC beta and zeta in concert with upregulation of PKC epsilon. Dev Biol 2003; 255(2): 407-22.
144. Klinz F, Bloch W, Addicks K, Hescheler J. Inhibition of phosphatidylinositol -3-kinase blocks development of functional embryonic cardiomyocytes. Exp Cell Res 1999; 247(1): 79-83.
145. Hescheler J, Halbach M, Egert U, et al. Determination of electrical properties of ES cell-derived cardiomyocytes using MEAs. J Electrocardiol 2004; 37 Suppl: 110-16.
146. Grey C, Mery A, Puceat M. Fine-tuning in Ca2+ homeostasis underlies progression of cardiomyopathy in myocytes derived from genetically modified embryonic stem cells. Hum Mol Genet 2005; 14(10): 1367-77.
147. Murashov AK, Pak ES, Katwa LC. Parallel development of cardiomyocytes and neurons in embryonic stem cell culture. Biochem Biophys Res Commun 2005; 332(3): 653-56.
148. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, et al. Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2. Cell 2007; 303-317.
149. Kwon C, Han Z, Olson EN, Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci USA 2005; 102(52): 18986-91.
150. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005; 436(7048): 214-20.
151. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA. Science 2007; 575-79.
152. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103(48): 18255-60.
153. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac myocyte hypertrophy. Nature Medicine 2007; In Press.
154. Strauss WM, Chen C, Lee CT, Ridzon D. Nonrestrictive developmental regulation of microRNA gene expression. Mamm Genome 2006; 17(8): 833-40.
155. Wang X, Wei G, Yu W, Zhao Y, Yu X, Ma X. Scalable producing embryoid bodies by rotary cell culture system and constructing engineered cardiac tissue with ES-derived cardiomyocytes in vitro. Biotechnol Prog 2006; 22(3): 811-18.
156. Guo XM, Zhao YS, Chang HX, et al. Creation of engineered cardiac tissue in vitro from mouse embryonic stem cells. Circulation 2006; 113(18): 2229-37.
157. Barili F, Dainese L, Topkara VK, Biglioli P, Polvani G. The future of human valve allografts: bioengineering and stem cells. Artif Organs 2005; 29(11): 923.
158. Shimizu T, Yamato M, Akutsu T, et al. Electrically communicating three-dimensional cardiac tissue mimic fabricated by layered cultured cardiomyocyte sheets. J Biomed Mater Res 2002; 60(1): 110-17.
159. Huang YC, Khait L, Birla RK. Contractile three-dimensional bioengineered heart muscle for myocardial regeneration. J Biomed Mater Res A 2007; 80(3): 719-31.
160. Eisenberg LM, Eisenberg CA. Embryonic myocardium shows increased longevity as a functional tissue when cultured in the presence of a noncardiac tissue layer. Tissue Eng 2006; 12(4): 853-65.
161. Akhyari P, Fedak PW, Weisel RD, et al. Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts. Circulation 2002; 106(12 Suppl 1): 1137-42.